Published in J Virol on July 25, 2007
Suppressive effects on the immune response and protective immunity to a JEV DNA vaccine by co-administration of a GM-CSF-expressing plasmid in mice. PLoS One (2012) 0.82
Regulatory T Cells Modulate DNA Vaccine Immunogenicity at Early Time via Functional CD4(+) T Cells and Antigen Duration. Front Immunol (2015) 0.81
Increased generation of HIV-1 gp120-reactive CD8+ T cells by a DNA vaccine construct encoding the chemokine CCL3. PLoS One (2014) 0.77
Differential Type I Interferon Signaling Is a Master Regulator of Susceptibility to Postinfluenza Bacterial Superinfection. MBio (2016) 0.77
Tolerogenic dendritic cells. Annu Rev Immunol (2001) 13.77
The nature of the principal type 1 interferon-producing cells in human blood. Science (1999) 10.90
Secretory products of macrophages. J Clin Invest (1987) 10.33
Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med (1999) 8.01
Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity (2001) 5.04
Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity (2003) 4.93
CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med (2001) 4.82
Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med (1988) 4.79
Interferons alpha and beta as immune regulators--a new look. Immunity (2001) 4.75
Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood (2000) 3.85
IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol (2001) 3.13
Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity (1995) 2.63
Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J Immunol (2001) 2.24
Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol (1987) 2.00
Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. Science (1992) 1.89
Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol (2002) 1.58
A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol (1998) 1.54
Imaging transgene expression in live animals. Mol Ther (2001) 1.43
Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infect Immun (2005) 1.34
Developing DNA vaccines that call to dendritic cells. J Clin Invest (2004) 1.24
Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol (2000) 1.24
Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses. Eur J Immunol (2004) 1.23
Inhibition of herpes simplex virus type 1 immediate-early gene expression by alpha interferon is not VP16 specific. J Virol (1996) 1.20
Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum Gene Ther (1995) 1.11
Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am J Physiol (1999) 1.05
Interferons inhibit onset of murine cytomegalovirus immediate-early gene transcription. Virology (1993) 1.00
Type I interferons potently suppress gene expression following gene delivery using liposome(-)DNA complexes. Mol Ther (2005) 1.00
Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo. J Virol (2004) 0.97
Interferon-alpha inhibits the murine cytomegalovirus immediate-early gene expression by down-regulating NF-kappa B activity. Virology (1995) 0.96
Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals. J Virol (2004) 0.87
Interleukin-1-mediated inhibition of cytomegalovirus replication is due to increased IFN-beta production. J Interferon Cytokine Res (2002) 0.85
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature (2002) 12.49
Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature (2002) 7.41
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol (2004) 4.36
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med (2006) 4.14
T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity (2004) 3.69
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Adaptive immune response of Vgamma2Vdelta2+ T cells during mycobacterial infections. Science (2002) 3.01
Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol (2005) 2.61
Dynamic immune responses maintain cytotoxic T lymphocyte epitope mutations in transmitted simian immunodeficiency virus variants. Nat Immunol (2005) 2.60
Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med (2006) 2.60
Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med (2010) 2.53
A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol (2005) 2.44
Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol (2005) 2.40
Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol (2003) 2.39
Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol (2010) 2.39
TRIM5alpha Modulates Immunodeficiency Virus Control in Rhesus Monkeys. PLoS Pathog (2010) 2.33
T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol (2009) 2.17
Simian-human immunodeficiency virus escape from cytotoxic T-lymphocyte recognition at a structurally constrained epitope. J Virol (2003) 2.15
A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog (2009) 2.09
Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. J Virol (2004) 2.09
Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS (2008) 2.06
Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol (2005) 2.01
Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol (2002) 1.88
Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol (2004) 1.86
A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci U S A (2008) 1.80
Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol (2005) 1.78
CCL3L1 and HIV/AIDS susceptibility. Nat Med (2009) 1.73
Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog (2011) 1.70
Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques. AIDS (2002) 1.69
Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J Virol (2006) 1.63
Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J Virol (2005) 1.63
Engineered T-cell receptor tetramers bind MHC-peptide complexes with high affinity. Nat Biotechnol (2004) 1.60
Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol (2003) 1.60
Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol (2002) 1.58
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc Natl Acad Sci U S A (2004) 1.55
Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol (2003) 1.53
Immune distribution and localization of phosphoantigen-specific Vgamma2Vdelta2 T cells in lymphoid and nonlymphoid tissues in Mycobacterium tuberculosis infection. Infect Immun (2007) 1.52
Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol (2008) 1.51
Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J Virol (2006) 1.51
Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol (2004) 1.49
T-cell dynamics during acute SIV infection. AIDS (2004) 1.46
Copy number variation of KIR genes influences HIV-1 control. PLoS Biol (2011) 1.44
Induction of an AIDS virus-related tuberculosis-like disease in macaques: a model of simian immunodeficiency virus- mycobacterium coinfection. Infect Immun (2002) 1.39
Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J Clin Invest (2004) 1.39
Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. Vaccine (2009) 1.38
Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J Virol (2008) 1.38
Magnitude and quality of vaccine-elicited T-cell responses in the control of immunodeficiency virus replication in rhesus monkeys. J Virol (2008) 1.36
Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol (2005) 1.36
Chemical adjuvants for plasmid DNA vaccines. Vaccine (2007) 1.34
Compensatory substitutions restore normal core assembly in simian immunodeficiency virus isolates with Gag epitope cytotoxic T-lymphocyte escape mutations. J Virol (2006) 1.33
Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population. AIDS (2011) 1.33
Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J Virol (2011) 1.32
Immune gene networks of mycobacterial vaccine-elicited cellular responses and immunity. J Infect Dis (2006) 1.30
Dysfunction of simian immunodeficiency virus/simian human immunodeficiency virus-induced IL-2 expression by central memory CD4+ T lymphocytes. J Immunol (2005) 1.29
Contributions of Mamu-A*01 status and TRIM5 allele expression, but not CCL3L copy number variation, to the control of SIVmac251 replication in Indian-origin rhesus monkeys. PLoS Genet (2010) 1.28
Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate. J Virol (2009) 1.28
Adaptive immune response of Vgamma2Vdelta2 T cells: a new paradigm. Trends Immunol (2003) 1.27
Critical role for IL-21 in both primary and memory anti-viral CD8+ T-cell responses. Eur J Immunol (2010) 1.27
Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing. J Virol (2010) 1.26
Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques. J Virol (2004) 1.25
Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol (2012) 1.24
Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine (2009) 1.24
Vaccine-elicited memory cytotoxic T lymphocytes contribute to Mamu-A*01-associated control of simian/human immunodeficiency virus 89.6P replication in rhesus monkeys. J Virol (2005) 1.24
Recruitment of different subsets of antigen-presenting cells selectively modulates DNA vaccine-elicited CD4+ and CD8+ T lymphocyte responses. Eur J Immunol (2004) 1.23
Thy1+ NK [corrected] cells from vaccinia virus-primed mice confer protection against vaccinia virus challenge in the absence of adaptive lymphocytes. PLoS Pathog (2011) 1.23
Generation of CD8+ T-cell responses by a recombinant nonpathogenic Mycobacterium smegmatis vaccine vector expressing human immunodeficiency virus type 1 Env. J Virol (2006) 1.22
Immunodomination in the evolution of dominant epitope-specific CD8+ T lymphocyte responses in simian immunodeficiency virus-infected rhesus monkeys. J Immunol (2006) 1.20
Clinical latency and reactivation of AIDS-related mycobacterial infections. J Virol (2004) 1.19
Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology (2007) 1.19
Vgamma2Vdelta2+ T cells and anti-microbial immune responses. Microbes Infect (2003) 1.18
Coping with viral diversity in HIV vaccine design: a response to Nickle et al. PLoS Comput Biol (2008) 1.17
Inhibition of adaptive Vgamma2Vdelta2+ T-cell responses during active mycobacterial coinfection of simian immunodeficiency virus SIVmac-infected monkeys. J Virol (2003) 1.16
HIV-specific functional antibody responses in breast milk mirror those in plasma and are primarily mediated by IgG antibodies. J Virol (2011) 1.15
In vivo natural killer cell depletion during primary simian immunodeficiency virus infection in rhesus monkeys. J Virol (2008) 1.15
The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev (2004) 1.15
Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol (2003) 1.15
Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS One (2011) 1.15
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A (2003) 1.14
Vaccine protection against functional CTL abnormalities in simian human immunodeficiency virus-infected rhesus monkeys. J Immunol (2002) 1.14
The TRIM5 gene modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys. J Virol (2011) 1.14
Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys. J Virol (2003) 1.13
Memory CD4+ T-lymphocyte loss and dysfunction during primary simian immunodeficiency virus infection. J Virol (2007) 1.13
The impact of a boosting immunogen on the differentiation of secondary memory CD8+ T cells. J Virol (2007) 1.13
Monitoring HIV vaccine trial participants for primary infection: studies in the SIV/macaque model. AIDS (2009) 1.12
Preservation of functional virus-specific memory CD8+ T lymphocytes in vaccinated, simian human immunodeficiency virus-infected rhesus monkeys. J Immunol (2006) 1.12
Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology (2012) 1.12
Simian immunodeficiency virus (SIV)-specific CD8+ T-cell responses in vervet African green monkeys chronically infected with SIVagm. J Virol (2008) 1.11